Novel Nanoliposomal Nitroglycerin Formulation for Cardiovascular Therapies
Novel formulation of NTG for potential use in conditions associated with the inflammatory process such as PAH, atherosclerosis, and diabetes A more potent formulation of NTG could be used in the current indications of chest pain and high blood pressure during surgery
None
20180177724
Background Leukocyte-endothelial cell (EC) adhesion is a hallmark of the inflammatory process, and is associated with diseases such as pulmonary arterial hypertension (PAH), atherosclerosis, and diabetes. This adhesion is inhibited by endogenous EC-derived nitric oxide (NO), which is significantly impaired in the aforementioned conditions. Thus, NO-releasing nitrates are being investigated as anti-inflammatory therapies. Nitroglycerin (NTG) is of particular interest among clinically-used nitrates because it spontaneously produces NO and also activates endothelial NO synthase (eNOS), the key NO-producing enzyme in ECs that is impaired in inflammatory conditions. However, NTG is not suitable for long-term clinical use due to loss of NTG sensitivity (tolerance) and endothelial dysfunction (cross-tolerance). Related Materials Tech ID/UC Case 28752/2016-346-0 Related Cases 2016-346-0
美国
